BRAF Q524L

CI-VAR-00003543Explore in graph →CIViC 3663

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
BRAF Q524L	Cetuximab	Predictive	D	Supports Sensitivity Response	3	submitted	EID12687 BRAF mutants (Q524L, L525R, V600E) were transfected into HEK293 cells and downstream ERK phosphorylation was measured by western blot. Treatment with cetuximab reduced phosphorylation in wild-type and… (full text at CIViC) PMID 28972961 · Shinozaki et al., 2017 · Open in CIViC	civic
Unmapped disease1unmapped disease
BRAF Q524L	(functional)	Functional	D	Does Not Support Gain Of Function	3	submitted	EID10017 BRAF mutants (Q524L, L525R, V600E) were transfected into HEK293 cells and downstream ERK phosphorylation was measured by western blot. ERK phosphorylation induced by L525R was similar to that induced … (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.